Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis.

Minerva cardioangiologica - 1 Oct 2018

De Vecchis Renato, Cesaro Arturo, Ariano Carmelina

Abstract excerpt

INTRODUCTION: According to 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension (PH), no specific drug is currently indicated for PH related to left heart disease (PH-LDH), i.e., the one secondary to left chronic heart failure (CHF), which coincides with the group 2 of the PH classification endorsed by the above-mentioned guidelines. Indeed, adoption of therapies that specifically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Echocardiography
Share to Exercise Test

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Failure

Share to Hospitalization

Share to Hypertension, Pulmonary

Share to Practice Guidelines as Topic

Share to Randomized Controlled Trials as Topic

Share to Ventricular Function, Left

Source

Identifiers

PMID: 28398017
DOI: 10.23736/S0026-4725.17.04382-1

Genes

PVR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis.PMID 28398017Read ↗

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Semantic proximity Read ↗

Effect of Beta Blockers on Exercise Capacity, Diastolic Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction: A Secondary Analysis of INDIE-HFpEF and RELAXSemantic proximity Read ↗

Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies.Semantic proximity Read ↗

Cardiovascular drugs approved for heart failure with reduced ejection fraction and/or post-myocardial infarction exert consistent effects in both populations: A meta-analysis and meta-regression of randomized controlled trialsSemantic proximity Read ↗

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.Semantic proximity Read ↗

Pulmonary hypertension associated to left heart disease: Phenotypes and treatment.Semantic proximity Read ↗

Statins for Heart Failure with Preserved Ejection Fraction: Current Evidence and PerspectivesSemantic proximity Read ↗

Mechanisms of current therapeutic strategies for heart failure: more questions than answers?Semantic proximity Read ↗

Left Ventricular Remodeling Response to SGLT2 inhibitors in Heart Failure: An Updated Meta-analysis of Randomized Controlled StudiesSemantic proximity Read ↗

Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes.Semantic proximity Read ↗

Heart failure with preserved ejection fraction: A systemic disease linked to multiple comorbidities, targeting new therapeutic options.Semantic proximity Read ↗

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.